Table 1

Total average costs of hospital procedures and medicines per patient for treating ALL with CAR-T and HCT. The CAR-T infusion period covers the time period from 8 weeks before to 6 weeks after the CAR-T infusion date; Year one data excludes infusion costs. The HCT period covers the time period from 15 weeks before to 8 weeks after the date of the procedure

	CAR-T cohort: average annual costs (US$)					NPV 3% total costs
	Infusion	Year 1	Year 2	Year 3*	Year 4*	NPV 3% total costs
Hospital procedures	50 676	41 740	14 022	4711	1582	106 926
Medicines (excluding price of CAR-T	5542	6351	507	40	3	11 870
Total treatment cost (excluding price for CAR-T)	56 217	48 091	14 529	4751	1586	118 795
Total treatment cost (including price for CAR-T)	531 217	48 091	14 529	4791	1589	579 999

	HCT cohort: average annual costs (US$)					NPV 3% total costs
	Infusion	Year 1	Year 2	Year 3	Year 4	NPV 3% total costs
Hospital procedures	17 241	9687	2617	22 589	24 007	69 043
Medicines	135 196	74 465	32 040	2223	1480	234 022
Total treatment cost	152 437	84 152	34 657	24 812	25 487	303 065

The CAR-T infusion period covers the time period from 8 weeks before to 6 weeks after the CAR-T infusion date; year 1 data excludes infusion costs. The HCT period covers the time period from 15 weeks before to 8 weeks after the date of the procedure.
*For years 3 and 4, CAR-T costs were extrapolated.
CAR-T, chimeric antigen receptor T-cell; HCT, haematopoietic cell transplant; NPV, net present value.